An investigation on behalf of investors of Aptinyx Inc. (NASDAQ: APTX) shares over potential securities laws violations by Aptinyx Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Aptinyx Inc. (NASDAQ: APTX) concerning whether a series of statements by Aptinyx Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Evanston, IL based Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx Inc. completed its initial publis offering (IPO) on June 21, 2018, offering $16.00 per share for net proceeds of $92.2 million. However, since the IPO shares of Aptinyx Inc. (NASDAQ: APTX) declined to as low as $2.96 per share on August 26, 2019.